Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes

@article{Sveen2016AberrantRS,
  title={Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes},
  author={Anita Sveen and Sami Kilpinen and Anja Ruusulehto and Ragnhild A Lothe and Rolf I. Skotheim},
  journal={Oncogene},
  year={2016},
  volume={35},
  pages={2413-2427}
}
Alternative splicing is a widespread process contributing to structural transcript variation and proteome diversity. In cancer, the splicing process is commonly disrupted, resulting in both functional and non-functional end-products. Cancer-specific splicing events are known to contribute to disease progression; however, the dysregulated splicing patterns found on a genome-wide scale have until recently been less well-studied. In this review, we provide an overview of aberrant RNA splicing and… 

Figures, Tables, and Topics from this paper

Alternative Splicing: Expanding the Landscape of Cancer Biomarkers and Therapeutics
TLDR
The need to further explore the cancer-specific splicing programs in order to obtain new insights in oncology is emphasized, and the recent advances in the identification of dysregulated splicing signatures on a genome-wide scale and their potential use as biomarkers are discussed.
Roles and mechanisms of alternative splicing in cancer — implications for care
TLDR
Antisense oligonucleotides offer promise to modulate cancer-relevant alternative splicing decisions, with proof of concept for this type of therapy demonstrated by Nusinersen, a first-in-class treatment for patients with spinal muscular atrophy.
The Cancer Spliceome: Reprograming of Alternative Splicing in Cancer
TLDR
A sufficient understanding of splicing deregulation in cancer is predicted to pave the way for novel and innovative RNA-based therapies.
Revealing the Determinants of Widespread Alternative Splicing Perturbation in Cancer.
TLDR
A network-based strategy, DrAS-Net, is developed to investigate more than 2.5 million variants across cancer types and link somatic mutations with cancer-specific splicing events, revealing how single-nucleotide changes can alter the repertoires of splicing isoforms.
The role of alternative splicing in cancer: From oncogenesis to drug resistance.
TLDR
An extensive overview of the latest findings in the field of regulation of splicing in cancer, including molecular mechanisms by which cancer cells harness alternative splicing to drive oncogenesis and evade anticancer drug treatment as well as splicing-based vulnerabilities that can provide novel treatment opportunities are provided.
Exploiting differential RNA splicing patterns: a potential new group of therapeutic targets in cancer
TLDR
Targeting aberrant splicing is an early but emerging field in cancer treatment and inhibitors of mutated splicing factors require improved specificity, as alternative and aberrantSplicing are often intertwined like two sides of the same coin.
A functional network of gastric-cancer-associated splicing events controlled by dysregulated splicing factors
TLDR
A robust network of dysregulated splicing associated with tumor invasion in gastric cancer is established and is a resource for identifying oncogenic splice forms, SFs and splicing-generated tumor antigens as biomarkers and therapeutic targets.
Signaling Pathways Driving Aberrant Splicing in Cancer Cells
TLDR
Current known mechanisms by which cancer cell signaling, including the mitogen-activated protein kinases (MAPK), phosphatidylinositol 3 (PI3K) and wingless (Wnt) pathways but also signals from the tumor microenvironment, modulate the activity or subcellular localization of the Ser/Arg rich proteins and heterogeneous nuclear ribonucleoproteins families of SFs are reviewed.
Aberrant RNA Splicing Events Driven by Mutations of RNA-Binding Proteins as Indicators for Skin Cutaneous Melanoma Prognosis
TLDR
Functional enrichment analysis revealed that these alternative splicing events (ASEs) may participate in tumor progress by regulating the modification process, cell-cycle checkpoint, metabolic pathways, MAPK signaling, PI3K-Akt signaling, and other important pathways in cancer.
Alternative splicing and cell survival: from tissue homeostasis to disease
TLDR
Emphasis is given to the role of this regulation in human cancer and in the response to chemotherapy, providing examples of how alternative splicing of apoptotic genes can be exploited therapeutically.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 296 REFERENCES
Alternative splicing in cancer: noise, functional, or systematic?
  • R. Skotheim, M. Nees
  • Biology, Medicine
    The international journal of biochemistry & cell biology
  • 2007
TLDR
The functional connection between the regulatory machinery (i.e., the spliceosome and its accessory proteins) and their global impact on qualitative transcript variation that are only now emerging from the use of genomic technologies such as microarrays are described.
Misregulation of pre-mRNA alternative splicing in cancer.
UNLABELLED Alternative splicing of mRNA precursors enables one gene to produce multiple protein isoforms with differing functions. Under normal conditions, this mechanism is tightly regulated in
Aberrant and Alternative Splicing in Cancer
TLDR
Antibodies against alternatively spliced products on cancer cells are currently in clinical trials, and competitive reverse transcription-PCR across regions of alternative splicing is being used as a simple diagnostic test.
Tissue-specific splicing factor gene expression signatures
TLDR
This work uses a computational approach to analyze microarray-based gene expression profiles of splicing factors from mouse, chimpanzee and human tissues and shows that brain and testis, the two tissues with highest levels of alternative splicing events, have the largest number ofSplicing factor genes that are most highly differentially expressed.
Alternative splicing: an emerging topic in molecular and clinical oncology.
TLDR
The current knowledge on the mechanisms governing abnormal alternativesplicing in cancer and the biological consequences associated with the alteration of splicing in some relevant cancer-related genes are summarized.
Splice variants as cancer biomarkers.
TLDR
The basic mechanism ofAlternative splicing, alternative splicing in cancer-associated genes, tools to identify splice variants, and the development of clinical tests based on alternatively spliced biomarkers are discussed.
Deregulation of splicing factors and breast cancer development.
TLDR
This review focuses on splicing factors and RNA-binding proteins that are themselves deregulated in breast cancer and implicated in cancer-related alternative splicing events.
The emerging role of splicing factors in cancer
TLDR
How recent links between cancer and altered expression of proteins implicated in splicing regulation are bringing the splicing machinery to the fore as a potential target for anticancer treatment is discussed.
Alternative Splicing and Its Impact as a Cancer Diagnostic Marker
TLDR
Taken together, the identification of alternative spliced variants as biomarkers to distinguish between normal and cancer cells could cast light on tumorigenesis.
RNA sequencing of cancer reveals novel splicing alterations
TLDR
This study systematically revealed splicing signatures of the three most common types of breast tumors using RNA sequencing and validated the presence of novel hybrid isoforms of critical molecules like CDK4, LARP1, ADD3, and PHLPP2.
...
1
2
3
4
5
...